Loyal Announces $45 Million Series B Financing led by Bain Capital Ventures for development of FDA-Approved Dog Lifespan Extension Drug.

Mar 21, 2024•over 1 year ago

Amount Raised

$45 Million

Round Type

series b

Atlanta

Investors

Todd & Rahul’s Angel FundQuiet CapitalCollaborative FundBox GroupFirst Round CapitalKhosla VenturesValor Equity PartnersBain Capital Ventures

Description

Loyal, a biotech company specializing in longevity drugs for dogs, has secured $45 million in Series B funding led by Bain Capital Ventures. The funding will support the development and expected launch of FDA-approved dog lifespan extension drugs.

Company Information

Company

Loyal

Location

Atlanta, Georgia, United States

About

One of the first companies to offer end-to-end digital and AI-powered solutions spanning the entirety of the patient journey, Loyal is the preferred software solution for improved care utilization among the nation's leading health systems and hospitals. From selecting a provider best suited for them to closing the feedback loop on their experience, patients who engage with healthcare networks via our proprietary platform quite simply, tend to be more loyal. Learn how to streamline patients' navigation of your health system and network of clinical services at LoyalHealth.com.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends